Kite Pharma to Present at the 2015 Jefferies Immuno-Oncology Summit in Boston
April 10, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., April 10, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Announces Publication in Science of Cancer Immunotherapy Articles Authored by Lead Collaborators at the National Cancer Institute and the Netherlands Cancer Institute
April 06, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., April 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Reports Full-Year and Fourth Quarter 2014 Financial Results
March 26, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., March 26, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 26th, 2015
March 25, 2015 21:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Strengthens Its T Cell Receptor (TCR) Cancer Gene Therapy Platform Through Acquisition of T-Cell Factory B.V. (TCF(TM))
March 17, 2015 08:00 ET
|
Kite Pharma, Inc.
- Kite Pharma EU Established as European Headquarters in Amsterdam, Appointing Ton N. M. Schumacher Ph.D. as its Chief Scientific Officer -
- Kite to Expand Product Pipeline in TCRs for the...
Kite Pharma to Present at the 2015 Barclays Global Healthcare Conference
March 06, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., March 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next Generation of Cancer Immunotherapy Products for Solid Tumors
March 02, 2015 08:00 ET
|
Kite Pharma, Inc.
-Focus on T Cell Response to Tumor-Specific Mutations-
-Expansion of TCR and CAR Product Pipeline-
SANTA MONICA, Calif., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a...
Kite Pharma to Present at the Cowen and Company 35th Annual Health Care Conference
February 23, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products
February 19, 2015 08:00 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
Kite Pharma to Present at the 17th Annual BIO CEO & Investor Conference
February 02, 2015 16:30 ET
|
Kite Pharma, Inc.
SANTA MONICA, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...